TiGenix publishes transparency notification pursuant to Article 14 of the Law of May 2, 2007

REGULATED INFORMATION
PRESS RELEASE

TiGenix publishes transparency notification pursuant to Article 14 of the Law of May 2, 2007

Leuven (Belgium) - October 17, 2014 - TiGenix NV (Euronext Brussels: TIG) publishes today a transparency notification pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.

It concerns a notification (received by TiGenix on October 17, 2014) made by the related companies Roche Holding AG (with address at Grenzacherstrasse 124, 4058 Basel, Switzerland) / Roche Finanz AG (with address at Grenzacherstrasse 122, 4058 Basel, Switzerland) following the passive crossing below the 3% threshold on November 22, 2013 by the group as a whole (compared to the denominator of 160,476,620 shares).

The chain of controlled undertakings through which the holdings are effectively held, is as follows: Roche Holding AG controls Roche Finanz AG.

For further details regarding this notification, we refer to our website: http://www.tigenix.com/en/page/26/shareholders.

For more information

Richard Simpson
Senior Consultant, Comfi SPRL
T: +32 494 578 278
richard@comfi.be

About TiGenix

TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, or donor-derived, expanded adipose-derived stem cells, known as eASCs, in inflammatory and autoimmune diseases. Two products from this technology platform are currently in clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn's disease patients. Cx611 is in Phase IIb for early rheumatoid arthritis, and in Phase Ib for severe sepsis. TiGenix also developed ChondroCelect, an autologous cell therapy product for cartilage repair of the knee, which was the first Advanced Therapy Medicinal Product (ATMP) to be approved by the European Medicines Agency (EMA). From June 2014, the marketing and distribution rights of ChondroCelect have been exclusively licensed to Sobi for the European Union (except for Finland, where it is distributed by the Finnish Red Cross Blood Service), Norway, Russia, Switzerland and Turkey, and the countries of the Middle East and North Africa. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain). For more information, please visit www.tigenix.com